Verastem Oncology reports positive RAMP 205 data in front-line pancreatic cancer
Compartilhar
Verastem Oncology (NASDAQ:VSTM) today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating its investigational combination regimen in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
